Publications by authors named "Ann Buchanan"

Claim this Profile
O
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.
Lisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, Elizabeth Kaudha, Grace M Ahimbisibwe, Ann M Buchanan

EBioMedicine· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of the Two-Drug Regimen Dolutegravir-Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-Label, Phase 3b Trial.
Thanyawee Puthanakit, Linda Aurpibul, Monica Lopez, Marcia Wang, Marika Ciuffa, Ann M Buchanan

J Acquir Immune Defic Syndr· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiometabolic Health Burden in Pediatric HIV: Unmet Need in the Contemporary Antiretroviral Therapy Era.
Elisa López, Talía Sainz, Sahera Dirajlal-Fargo, Jennifer Jao, Jorge Pinto, Ann M Buchanan

Cureus· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results.
Helena Rabie, Dwight E Yin, Shawn Ward, Yasha Rani, Lauren Ziemba, Ann M Buchanan

Pediatr Infect Dis J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspective.
Ann M Buchanan, Adrie Bekker, Hardik Chandasana, Ralph DeMasi, Zrinka Lulic

Int J Antimicrob Agents· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Model-Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed-Dose Combination Approval in Children Living with HIV-1.
Hardik Chandasana, Ann M Buchanan, Michael McKenna, Cindy Brothers, Stephen Hyatt

J Clin Pharmacol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics.
Hardik Chandasana, Siobhán Hayes, Ann M Buchanan, Cynthia Brothers, Andrew Wiznia

AIDS· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.
Hardik Chandasana, Mita Thapar, Siobhan Hayes, Mark Baker, Diana M Gibb, Ann Buchanan

Clin Pharmacokinet· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.
Kristina M Brooks, Jennifer J Kiser, Lauren Ziemba, Shawn Ward, Yasha Rani, Ann M Buchanan

Lancet HIV· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Food on the Pediatric Dispersible Tablet Formulations of TRIUMEQ and DOVATO in Healthy Adult Participants.
Hardik Chandasana, Ryan Marnoch, Michael McKenna, Julia Double, Ciara Seal, Ann Buchanan

Pharmaceutics· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
Theodore D Ruel, Edward P Acosta, Jessica P Liu, Kathryn P Gray, Kathleen George, Ann M Buchanan

Lancet HIV· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.
Rajendra P Singh, Kimberly K Adkison, Mark Baker, Ridhi Parasrampuria, Allen Wolstenholme, Ann M Buchanan

Pediatr Infect Dis J· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
Cindy Vavro, Theodore Ruel, Andrew Wiznia, Nicole Montañez, Keith Nangle, Ann M Buchanan

Antimicrob Agents Chemother· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision targeting of the plasminogen activator inhibitor-1 mechanism increases efficacy of fibrinolytic therapy in empyema.
Galina Florova, René A Girard, Ali O Azghani, Krishna Sarva, Ann Buchanan

Physiol Rep· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presumptive Primary Cerebral T-Cell Lymphoma in a White-Tailed Deer (Odocoileus virginianus).
Josué Díaz-Delgado, Alexis Templeton, Pamela J Ferro, Cinthya Cirqueira, Kátia Groch, Ann Buchanan

J Comp Pathol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukemic histiocytic sarcoma in a captive common squirrel monkey (Saimiri sciureus) with Saimiriine Gammaherpesvirus 2 (Rhadinovirus), Saimiri sciureus lymphocryptovirus 2 (Lymphocryptovirus) and Squirrel monkey retrovirus (β-Retrovirus) coinfection.
Ann Buchanan, Josué Díaz-Delgado, Gaya Balamayooran, Maritza Anguiano, Kátia Groch

J Med Primatol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Rolando M Viani, Theodore Ruel, Carmelita Alvero, Terry Fenton, Edward P Acosta, Ann M Buchanan

J Pediatric Infect Dis Soc· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
Rajendra P Singh, Jafar S B Shaik, Nancy Skoura, Shashidhar Joshi, Trevor Shreeves, Ann M Buchanan

J Acquir Immune Defic Syndr· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Catherine Orrell, Debbie P Hagins, Elena Belonosova, Norma Porteiro, Sharon Walmsley, Ann M Buchanan

Lancet HIV· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low- and High-Mineral-Content Water on the Tablet in Healthy Adults.
Ann M Buchanan, Michael Holton, Ian Conn, Mark Davies, Mike Choukour

Clin Pharmacol Drug Dev· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania.
Dorothy E Dow, Werner Schimana, Balthazar M Nyombi, Blandina T Mmbaga, Aisa M Shayo, Ann M Buchanan

AIDS Res Hum Retroviruses· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women.
Christine Trezza, Susan L Ford, Elizabeth Gould, Yu Lou, Chuyun Huang, Ann M Buchanan

Br J Clin Pharmacol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects.
Yu Lou, Ann M Buchanan, Shuguang Chen, Susan L Ford, Elizabeth Gould

Clin Pharmacol Drug Dev· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models.
Andrey A Komissarov, Galina Florova, Ali O Azghani, Ann Buchanan, Jake Boren

Am J Physiol Lung Cell Mol Physiol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.
Lisa L Ross, Ivy H Song, Niki Arya, Mike Choukour, Jian Zong, Ann M Buchanan

BMC Infect Dis· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis